drugset / Trial / NCT02312531

Prevention for Mother-to-infant Transmission of HBV

NCT02312531

Completed 28 enrolled Xi'an Jiaotong University
Non-randomizedParallel-groupOpen-labelPrevention

Summary

In this study, HBV-infected pregnant women were divided into two groups, those who received and those who did not receive hepatitis B immunoglobulin (HBIG) during pregnancy. In the mothers, the changes in HBV serum markers (hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb), HBeAg, hepatitis B core antibody (HBcAb)), and the DNA load were investigated. Immunohistochemical staining with custom-made antibodies against HBIG revealed both the level and distribution of HBIG in placentas. The protective mechanism of HBIG administrated during pregnancy was explored.

Timeline

Start
2012-05
Primary completion
2014-05
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Hepatitis B Immunoglobulin Protein / enzyme biologic 200 iu